CVS Health (CVS) Q4 2025 earnings review
Retail Resurgence Masks Insurance Weakness
CVS Health closed FY25 with record revenues topping $402 billion, driven by a standout performance in the Pharmacy & Consumer Wellness segment. However, the bottom line tells a different story: Q4 Adjusted EPS fell 8.4% YoY to $1.09, missing the growth narrative. While the retail pharmacy business is firing on all cylinders with nearly 10% same-store script growth, the Health Care Benefits (Aetna) segment remains a significant drag, posting a widened operating loss of $676 million in the quarter. Management confirmed 2026 EPS guidance but quietly slashed cash flow expectations by $1 billion.
🐂 Bull Case
Pharmacy & Consumer Wellness (PCW) is accelerating. Q4 revenue jumped 12.4% and adjusted operating income rose 8.7%. Same-store prescription volume surged 9.7%, proving the 'front door' strategy is capturing significant market share.
Despite Q4 noise, management confirmed FY26 Adjusted EPS guidance of $7.00-$7.20. This suggests confidence that the worst of the Medicare Part D seasonality and restructuring pains are contained in 2025.
🐻 Bear Case
Health Care Benefits (Aetna) posted an adjusted operating loss of $676 million, significantly worse than the $439 million loss a year ago. While management blames IRA-driven seasonality, the widening loss indicates underlying utilization or pricing pressures persist.
A major red flag: 2026 Cash Flow from Operations guidance was lowered to 'at least $9.0 billion' from the previous 'at least $10.0 billion.' A $1 billion reduction in expected cash generation contradicts the narrative of a stabilizing business.
⚖️ Verdict: ⚪
Neutral. The operational turnaround in Retail is impressive and undeniable. However, the insurance business (Aetna) is still posting deepening losses in Q4, and the $1 billion cut to forward cash flow guidance suggests the '2026 recovery' might be more capital-intensive or less profitable than initially advertised.
Key Themes
Retail Pharmacy Acceleration
The Pharmacy & Consumer Wellness segment is accelerating. Revenue growth hit 12.4% in Q4, up from 11.9% for the full year. Crucially, same-store prescription volume grew 9.7% in Q4 (vs 8.0% for the full year), indicating momentum is building. The Rite Aid file acquisition is paying off, and utilization remains robust.
Health Care Benefits Seasonality or Structural Issue?
Management attributes the $676M Q4 operating loss in HCB to 'changes in the seasonality of the Medicare Part D program due to the IRA.' However, the loss widened by $237M YoY. If this were purely statutory seasonality, pricing adjustments should have mitigated the impact. The MBR remained flat at a high 94.8%, but the absolute dollar loss indicates continued difficulty in managing medical costs relative to premiums in the fourth quarter.
Cash Flow Outlook Deterioration
In the guidance section, CVS explicitly lowered 2026 Cash Flow from Operations expectations from $10.0B to $9.0B. No specific reason was provided in the release text. For a company focused on deleveraging and maintaining dividends ($1.7B paid in Q4), a 10% reduction in forward operating cash flow is a material concern regarding working capital efficiency or expected cash earnings quality.
Health Services Revenue vs. Claims Divergence
Health Services (Caremark/Oak St) revenue grew 9.0% YoY despite Pharmacy Claims Processed falling 1.5%. This divergence highlights the impact of 'pharmacy drug mix and brand inflation.' While volume is down, CVS is extracting more revenue per claim, likely driven by high-cost specialty drugs (GLP-1s, etc.), supporting a 9.2% increase in segment operating income.
Tax Benefit Distortion
GAAP Net Income for Q4 was heavily distorted by a one-time tax benefit. The effective tax rate was (115.9)% due to a 'worthless stock deduction' from a bankrupt subsidiary (Omnicare). This generated a ~$1.9B non-cash benefit. Investors must look strictly at Adjusted EPS ($1.09) to understand true economic performance, which was down YoY.
Government Business Dependence
In the HCB segment, Government premiums (Medicare/Medicaid) grew 19.8% YoY to $26.6B, while Commercial premiums fell 14.7% to $7.5B. CVS is increasingly becoming a government-sponsored entity proxy. This increases regulatory risk (Star ratings, reimbursement rates) while reducing exposure to the commercial employer market.
Other KPIs
Stable. The MBR was 94.8% in Q4, identical to 24Q4. While stability is better than deterioration, 94.8% is an incredibly high ratio (leaving only 5.2% for admin costs and profit), resulting in the segment's operating loss. Full-year MBR improved to 91.2% from 92.5%.
Decelerating. Consolidated adjusted operating margin compressed from 2.8% in 24Q4 to 2.5% in 25Q4. This compression is driven by the Health Care Benefits loss and tighter margins in Health Services.
Decelerating. DCP dropped significantly from 42.5 days in Q3 2025 to 38.9 days. A drop in DCP often signals faster payments to providers or a release of reserves; however, if reserves were released aggressively to support earnings, this could leave less cushion for future quarters.
Guidance
Accelerating. The midpoint ($7.10) implies 5.2% growth over FY25 Adjusted EPS of $6.75. This represents a return to growth after a volatile 2025.
Decelerating/Negative Revision. Guidance was cut from 'at least $10.0 billion.' This implies a decline from FY25's actual result of $10.6 billion. A projected ~15% drop in cash flow despite projected earnings growth is a significant disconnect.
Accelerating. Massive jump from FY25 GAAP EPS of $1.39, primarily due to the non-recurrence of the $5.7B goodwill impairment and litigation charges recorded in 2025.
Key Questions
Reason for Cash Flow Guidance Cut
You lowered 2026 Cash Flow from Operations guidance by $1 billion (from $10B to $9B). What specific working capital dynamics or payment timing shifts drove this reduction?
Health Care Benefits Seasonality vs. Reality
You attribute the Q4 HCB loss to IRA-driven seasonality, yet the operating loss widened by nearly $240 million YoY. How much of this widening was due to underlying medical cost trend deterioration versus purely statutory changes?
Commercial Business Erosion
Commercial premium revenue in HCB dropped nearly 15% YoY in Q4. Is this a deliberate exit from unprofitable accounts, or are you losing share to competitors, and when does this segment stabilize?
Reserve Release Impact
Days Claims Payable fell sharply to 38.9 days from 42.5 days in Q3. Did reserve releases flatter the full-year MBR of 91.2%, and does this leave the balance sheet exposed for 2026?